(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.

被引：0
|
作者：
Francolini, Giulio
Di Cataldo, Vanessa
Detti, Beatrice
Garlatti, Pietro
Caini, Saverio
Bruni, Alessio
Ingrosso, Gianluca
D'Angelillo, Rolando Maria
Alitto, Anna Rita
Augugliaro, Matteo
Triggiani, Luca
Parisi, Silvana
Facchini, Gaetano
Banini, Marco
Simontacchi, Gabriele
Desideri, Isacco
Meattini, Icro
Valicenti, Richard K.
Livi, Lorenzo
机构：
[1] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Inst Canc Res Prevent & Clin Network, Canc Risk Factors & Life Style Epidemiol Unit, Florence, Italy
[4] Univ Hosp Modena, Dept Oncol & Hematol, Radiotherapy Unit, Modena, Italy
[5] Univ Perugia, Radiat Oncol Sect, Dept Med & Surg, Perugia, Italy
[6] Univ Roma Tor Vergata, Radiat Oncol, Dept Biomed & Prevent, Rome, Italy
[7] Fdn Policlin Univ A Gemelli IRCCS, UOC Radioterapia Oncol, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy
[8] Azienda USL IRCCS Reggio Emilia, Unit Radiotherapy, Reggio Emilia, Italy
[9] Univ Brescia, Dept Radiat Oncol, Brescia, Italy
[10] Univ Messina, Radiat Oncol Unit, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy
[11] SM Grazie Hosp, Med Oncol Unit, Naples, Italy
[12] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-137-3222-3876-5567; 130-540-543-12277-2683; 261-265; 261-566-11347; 3282-270-434-2806; 283-2494-5577-2829; 7; 5; 3; 2; 162; 175; 3617; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [41] Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study
    Du, Hong
    Xie, Wenjuan
    Chen, Wenqiang
    Wang, Yu
    Liao, Yong
    Qiu, Mingxing
    Li, Jun
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy
    Halabi, Susan
    Armstrong, Andrew J.
    Sartor, A. Oliver
    De Bono, Johann Sebastian
    Kaplan, Ellen B.
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
    Saad, Fred
    Hotte, Sebastien
    North, Scott
    Eigl, Bernie
    Chi, Kim
    Czaykowski, Piotr
    Wood, Lori
    Pollak, Michael
    Berry, Scott
    Lattouf, Jean-Baptiste
    Mukherjee, Som D.
    Gleave, Martin
    Winquist, Eric
    CLINICAL CANCER RESEARCH, 2011, 17 (17) : 5765 - 5773
  • [44] Association of body composition with survival and efficacy of first-line treatment in patients with castration-resistant prostate cancer
    Joung, Jae Young
    Pak, Sahyun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
    Alamiri, Jamal
    Ahmed, Mohamed E.
    Andrews, Jack R.
    Dundar, Ayca
    Motterle, Giovanni
    Karnes, Jeffrey
    Kwon, Eugene D.
    Bryce, Alan Haruo
    Kendi, Ayse T.
    Bold, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Treatment outcomes of patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC) on first line docetaxel chemotherapy at University Malaya Medical Centre
    Khoo, J. Y-Y
    Alip, A.
    Saad, M.
    Ong, T. A.
    BJU INTERNATIONAL, 2016, 118 : 32 - 32
  • [47] PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline
    Clarke, N. W.
    Armstrong, A. J.
    Thiery-Vuillemin, A.
    Oya, M.
    Shore, N.
    Procopio, G.
    Guedes, J. D.
    Arslan, C.
    Mehra, N.
    Parnis, F.
    Brown, E.
    Schlurmann, F.
    Joung, J. Y.
    Sugimoto, M.
    Sartor, O.
    Poehlein, C.
    Barker, L.
    Degboe, A.
    Saad, F.
    EUROPEAN UROLOGY, 2023, 83
  • [48] Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1)
    Broyelle, Antonin
    Bimbai, Andre-Michel
    Carnot, Aurelien
    Pannier, Diane
    Makhloufi, Samira
    Ryckewaert, Thomas
    Penel, Nicolas
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
    Clarke, Noel W.
    Armstrong, Andrew J.
    Oya, Mototsugu
    Shore, Neal
    Procopio, Giuseppe
    Guedes, Joao Daniel
    Arslan, Cagatay
    Mehra, Niven
    Parnis, Francis
    Brown, Emma
    Schlurmann, Friederike
    Joung, Jae Young
    Sugimoto, Mikio
    Sartor, Oliver
    Poehlein, Christian
    McGuinness, David
    Degboe, Arnold
    Saad, Fred
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 394 - 406
  • [50] Phase II Trial of Oxaliplatin and Capecitabine After Progression to First-Line Chemotherapy in Androgen-Independent Prostate Cancer Patients
    Gasent Blesa, Joan Manel
    Giner Marco, Vicente
    Giner-Bosch, Vicente
    Cerezuela Fuentes, Pablo
    Alberola Candel, Vicente
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 155 - 159
12345